Stay updated with breaking news from Network Trials Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data...
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data...
STOCKHOLM, March 11, 2022 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating
Antibody is first of three tau drugs to be evaluated Clinical trial participant Taylor Hutton (left) meets with Randall J. Bateman, MD, director of the global DIAN-TU Alzheimer’s clinical trial in 2018. Hutton’s family has a history of early-onset Alzheimer’s disease. The DIAN-TU is launching three new arms to evaluate experimental Alzheimer’s drugs targeting the protein tau. (Photo: Matt Miller/School of Medicine) March 15, 2021 SHARE A worldwide clinical trial aimed at finding treatments for Alzheimer’s disease has expanded to include investigational drugs targeting a harmful f...